Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.170
-0.020 (-1.68%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Marker Therapeutics Employees
Marker Therapeutics had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
$1,318,216
Profits / Employee
-$2,146,263
Market Cap
12.53M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
MRKR News
- 22 days ago - Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference - GlobeNewsWire
- 23 days ago - Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results - GlobeNewsWire
- 2 months ago - Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 4 months ago - Marker Therapeutics Announces $16.1 Million Private Placement - GlobeNewsWire
- 4 months ago - Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - GlobeNewsWire
- 4 months ago - Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer - GlobeNewsWire
- 4 months ago - Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium - GlobeNewsWire
- 5 months ago - Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit - GlobeNewsWire